This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Kalos Therapeutics is a biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. [1]
Kalos has been covered by ABC News [2] on Good Morning America, and profiled in Business Week. [3] The company aggressively targets diseases caused by an abnormally high growth rate of cells (hyper proliferation), [4] and is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.[5]
References
editExternal Links